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BACKGROUND. Radium-223 prolongs overall survival in patients with castration-resistant
prostate cancer (CRPC) and symptomatic bone metastases, regardless of prior docetaxel.
Whether or not chemotherapy can be safely administered following radium-223 treatment is
of clinical importance. An exploratory analysis of prospectively collected data, from the
ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) patient subgroup who received
chemotherapy after radium-223 or placebo treatment, was conducted to evaluate the safety
and efficacy of chemotherapy following radium-223.
METHODS. In ALSYMPCA, CRPC patients with symptomatic bone metastases and no
visceral metastases were randomized 2:1 to receive six injections of radium-223 (50 kBq/kg IV)
or placebo plus best standard of care, stratified by prior docetaxel, baseline alkaline
phosphatase, and current bisphosphonate use. In this exploratory analysis, chemotherapy
agents administered following study treatment were identified; timing and duration were
calculated. Hematologic safety was reviewed, and overall survival analyzed.
RESULTS. Overall, 142 radium-223 and 64 placebo patients received subsequent chemother-
apy; most common were docetaxel (70% radium-223, 72% placebo) and mitoxantrone (16%
radium-223, 20% placebo). The majority of patients (61% radium-223, 58% placebo) had
received prior docetaxel. Radium-223 patients started subsequent chemotherapy later than
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placebo patients; chemotherapy duration was similar between groups. In radium-223 and
placebo patients receiving subsequent chemotherapy, median hematologic values (hemoglo-
bin, neutrophils, and platelets) remained nearly constant up to 18 months following start of
chemotherapy, regardless of prior docetaxel treatment. A low percentage of patients in both
groups had grades 3–4 hematologic values (<10%). Platelet count decline, from last
measurement before chemotherapy, was numerically greater in radium-223 versus placebo
patients. Median overall survivals from start of chemotherapy were 16.0 and 15.8 months
following radium-223 and placebo, respectively.
CONCLUSIONS. Chemotherapy following radium-223, regardless of prior docetaxel,
is feasible and appears to be well tolerated in patients with CRPC and symptomatic
bone metastases. Prostate 76:905–916, 2016.
# 2016 The Authors. The Prostate published by Wiley Periodicals, Inc.
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INTRODUCTION
Radium-223 dichloride (radium-223) is a calcium
mimetic that specifically targets bone. It decays by
emitting high-energy alpha particles that penetrate
tissue only to a depth of about 2–10 cell diameters
(<100mM), resulting in highly localized cell killing
with minimal damage to surrounding normal tissue
including bone marrow cells [1–3]. As a result,
radium-223 presents less risk to cells in the bone
marrow than external beam radiation therapy (EBRT)
and the radiation emitted by other radionuclides used
in cancer therapy.
The phase 3 ALSYMPCA (ALpharadin in SYMptom-
atic Prostate CAncer) trial with radium-223 in patients
with CRPC and symptomatic bone metastases enrolled
both patients who had received prior docetaxel and
patients who had not [4], unlike other pivotal trials that
enrolled docetaxel-na€ıve or post-docetaxel patients only
[5–10]. In ALSYMPCA, radium-223, compared with
placebo, prolonged median overall survival (14.9 vs.
11.3 months) and reduced risk of death by 30% (hazard
ratio [HR] 0.70; 95%CI: 0.58–0.83; P< 0.001), regardless
of whether patients had received prior docetaxel
(HR 0.70) or not (HR 0.69), establishing the benefits
of radium-223 irrespective of prior docetaxel expo-
sure [4,11].
Radium-223 was well tolerated regardless of prior
docetaxel exposure, with a low overall incidence of
grades 3–4 myelosuppression [11]. Furthermore, prelim-
inary results from an ongoing phase I/IIa study show
that a radium-223 plus docetaxel combination therapy
is feasible, provided that the docetaxel dose is attenu-
ated and radium-223 is dosed less frequently [12].
The impact of radium-223 on the safety of subse-
quently administered chemotherapy has not been
specifically studied. There has been a reluctance to
administer chemotherapy after radioisotope therapy,
because of concern that radiation effects in the bone
marrow could compromise the safety of chemother-
apy [13]. Also, as hematologic parameters often
decline over the course of the disease regardless of
therapy, hematologic adverse events (AEs) and bone
marrow failure may complicate the clinical course of
patients with advanced CRPC [14,15]. An exploratory
analysis of prospectively collected data, from the
ALSYMPCA patient subgroup who received chemo-
therapy after completing their assigned study drug
treatment, was conducted to evaluate the safety of
chemotherapy following radium-223.
METHODS
ALSYMPCA Study Design and Patients
ALSYMPCA was a randomized phase III, double-
blind, placebo-controlled trial conducted at 136 cen-
ters in 19 countries comparing the efficacy and safety
of radium-223 plus best standard of care (BSoC) with
placebo plus BSoC in the treatment of patients with
CRPC, at least two bone metastases, symptomatic
bone disease (either regular analgesic use or treatment
with EBRT within the previous 12 weeks, for cancer-
related bone pain), and no known visceral metasta-
ses [4]. BSoC was defined as the routine care provided
at each center (e.g., local EBRT, glucocorticoids, anti-
androgens, ketoconazole, or estrogens such as diethyl-
stilbestrol or estramustine). Chemotherapy, hemibody
external radiotherapy, and other systemic radionu-
clides were not permitted during the period from first
injection to four weeks after last injection of study
drug.
ALSYMPCA eligibility requirements have been
published in detail elsewhere [4]. Patients should
have received prior docetaxel if available or, if not,
were considered either unfit for docetaxel or declined
the treatment. The primary end point was overall
survival. Safety was assessed on the basis of AEs,
hematologic values, clinical laboratory values, and
findings on electrocardiography and physical exami-
nation. The follow-up period was three years. The
study protocol was reviewed and approved by the
906 Sartor et al.
The Prostate
institutional review board at each participating center,
and all patients provided written informed consent.
Randomization and Masking
In ALSYMPCA, patients were randomized 2:1
to receive six intravenous injections of radium-223
(50 kBq/kg IV) or matching placebo once every four
weeks and were stratified by prior docetaxel use (yes
vs. no), baseline alkaline phosphatase level (<220U/L
vs. 220U/L), and current bisphosphonate use (yes
vs. no). Randomization was done with an interactive
voice response system, taking into account trial
stratification factors. The randomization number was
provided to the site investigators, but the assigned
treatment was not. Because radium-223 is radioactive,
an individual not masked to treatment at each center
calculated study drug volume and filled the syringe
for masked distribution. All others (patients, inves-
tigators, and study funders) were masked to the
allocated treatment group.
Patients included in this exploratory analysis were
the subgroup of all randomized patients who received
subsequent chemotherapy after treatment with
radium-223 or placebo. Therefore, the comparability
of radium-223 and placebo patients who received
subsequent chemotherapy is not assured by the initial
randomization of the original study.
Procedures
Chemotherapy was not permitted within the four
weeks prior to randomization, during the study treat-
ment period, or within four weeks after the last
injection of study drug but was permitted at the
investigator’s discretion thereafter. During the follow-
up period, complete blood counts (CBCs) were con-
ducted at each of nine follow-up visits: one visit every
two months for the first six months, and every four
months thereafter. CBC schedules had no clear relation-
ship to chemotherapy administered because of varying
chemotherapy start times among patients. From
12 weeks after the last study treatment, AEs were
recorded only if considered to be related to study drug.
Outcomes—Exploratory Analysis
In this analysis, hematologic safety and overall
survival were assessed among patients in the chemo-
therapy and docetaxel post-study drug subgroups
who had previously received radium-223 or placebo.
AEs were graded according to the Common Terminol-
ogy Criteria for Adverse Events (CTCAE). Overall
survival was defined as time from start of chemother-
apy to date of death.
Statistical Analysis
This exploratory analysis includes prospectively
collected data up to the ALSYMPCA study cutoff date
of March 2014. Analyses were not powered to assess
differences between radium-223 and placebo within
the chemotherapy or docetaxel post-study drug sub-
groups. The chemotherapy post-study drug subgroup
included patients who received any chemotherapy
following treatment with radium-223 or placebo.
The docetaxel post-study drug subgroup included
patients who received docetaxel following treatment
with radium-223 or placebo (and may have received
one or more different types of chemotherapy). Time
from randomization to start of chemotherapy, time
from end of study treatment to start of chemotherapy,
duration of first chemotherapy, and time from first
chemotherapy to stop of last chemotherapy (from
chemotherapy start to end of treatment or database
lock if still on treatment) were calculated using
descriptive statistics. CBCs were summarized by
2-month protocol-specified intervals using descriptive
statistics. Hazard ratios were calculated using a Cox
proportional hazards regression model. Subgroup
analyses were performed to assess treatment effects
based on prior docetaxel use. Fisher’s exact test was
used to calculate P values for patients with hemato-
logic laboratory values corresponding to grade three
or four AEs. Maximum change from baseline in
platelets by prior docetaxel use was assessed using
the Wilcoxon rank sum test. This trial is registered at
ClinicalTrials.gov (NCT00699751).
RESULTS
A total of 921 patients were enrolled in
ALSYMPCA between June 2008 and February 2011,
614 in the radium-223 group and 307 in the placebo
group (Fig. 1). A total of 407 (66%) radium-223 and
168 (55%) placebo patients entered long-term follow-
up. The chemotherapy post-study drug subgroup
comprises 206 (22%) patients and includes 142 (23%)
patients from the radium-223 group and 64 (21%)
patients from the placebo group who received chemo-
therapy following study treatment (Fig. 1). Demo-
graphics and baseline characteristics, including prior
docetaxel use and baseline hemoglobin and platelet
values, for patients in the chemotherapy post-study
drug subgroup were similar between radium-223 and
placebo groups. The majority of radium-223 (87
[61%]) and placebo (37 [58%]) patients in the chemo-
therapy post-study drug subgroup had also received
docetaxel prior to study treatment (Table I).
Compared with the entire ALSYMPCA intent-to-
treat (ITT) population, the chemotherapy post-study
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drug subgroup were somewhat younger and had
less extensive disease (Fig. 1), and a higher percentage
of patients in the chemotherapy post-study drug
subgroup had received all six injections of study
drug (Table II). Within the chemotherapy post-study
drug subgroup, more radium-223 patients (79%)
received all six injections compared with placebo
patients (58%) (Table II), and 79% and 88% of
radium-223 and placebo patients, respectively, with-
drew early from the study (Fig. 1). Primary reasons
for patient withdrawal are listed in Supplementary
Table SI.
Chemotherapy Following Study Drug
Docetaxel was the most commonly administered
chemotherapy agent, received by 70% (100/142) and
72% (46/64) of radium-223 and placebo patients,
respectively. Other commonly administered chemo-
therapy agents included mitoxantrone (16% [23/142]
radium-223, 20% [13/64] placebo), cyclophosphamide
(10% [14/142] radium-223, 11% [7/64] placebo), estra-
mustine (4% [6/142] radium-223, 8% [5/64] placebo),
and carboplatin (3% [4/142] radium-223, 5% [3/64]
placebo). Patients in the chemotherapy post-study
drug subgroup may have received one or more
chemotherapy regimens. There was a longer time
from randomization to start of chemotherapy for
radium-223 (9.1 months) compared with placebo
patients (7.5 months). The median time from the last
dose of study drug (radium-223 or placebo) to the
first dose of chemotherapy was 3.8 months for
radium-223 and 2.6 months for placebo. Median
duration of first chemotherapy was 4.6 months in the
radium-223 group and 4.2 months in the placebo
group (Table III).
Hematologic Laboratory Values
Median values for hematologic laboratory parame-
ters (hemoglobin, neutrophils, and platelets) from last
measurement before start of chemotherapy (baseline)
to 18 months following start of first chemotherapy are
shown for both treatment groups in the chemotherapy
post-study drug subgroup (Table IV). Although pa-
tient dropout rate during this period was high, it was
generally balanced between treatment groups (Fig. 1).
Median baseline values for neutrophils and platelets
were somewhat lower for patients in the radium-223
group than for the placebo group (Table IV). The
percentage of patients with hematologic values corre-
sponding to AEs of CTCAE grade 3 or 4 from baseline
Fig. 1. Consort diagram. Safety population includes patients who received at least one injection of study drug. One patient in the
placebo group received one injection of radium-223 (week 0) and is included in the radium-223 safety analysis. †Baseline refers to time of
last visit prior to start of first post-study chemotherapy. Duration of time in study after start of post-study chemotherapy is defined as time
from start of chemotherapy to last registered visit. ‡Percentage of the chemotherapy post-study drug subgroup (142 radium-223, 64 placebo).
908 Sartor et al.
The Prostate
T
A
B
L
E
I.
D
em
o
gr
ap
hi
cs
an
d
B
as
el
in
e
C
ha
ra
ct
er
is
ti
cs
fo
r
P
at
ie
nt
s
in
th
e
C
he
m
o
th
er
ap
y
P
o
st
-S
tu
dy
D
ru
g
S
ub
gr
o
up
V
er
su
s
th
e
A
L
S
Y
M
P
C
A
In
te
nt
-t
o
-T
re
at
(I
T
T
)
P
o
pu
la
ti
o
na
C
he
m
ot
he
ra
py
po
st
-s
tu
d
y
d
ru
g
su
bg
ro
up
A
L
SY
M
PC
A
IT
T
po
pu
la
ti
on
C
ha
ra
ct
er
is
ti
c
R
ad
iu
m
-2
23
n
¼
14
2
Pl
ac
eb
o
n
¼
64
R
ad
iu
m
-2
23
N
¼
61
4
Pl
ac
eb
o
N
¼
30
7
M
ed
ia
n
ag
e
(r
an
ge
),
y
68
(4
9–
85
)
68
(5
0–
82
)
71
(4
9–
90
)
71
(4
4–
94
)
A
ge
>
75
y,
n
(%
)
20
(1
4)
12
(1
9)
17
1
(2
8)
90
(2
9)
C
au
ca
si
an
ra
ce
,n
(%
)
13
3
(9
4)
60
(9
4)
57
5
(9
4)
29
0
(9
5)
B
as
el
in
e
E
C
O
G
PS
1
,n
(%
)
13
6
(9
6)
57
(8
9)
53
6
(8
7)
26
5
(8
6)
E
xt
en
t
of
d
is
ea
se
,n
(%
)
<
6
m
et
as
ta
se
s
33
(2
4)
15
(2
3)
10
1
(1
7)
38
(1
2)
6–
20
m
et
as
ta
se
s
60
(4
3)
34
(5
3)
25
8
(4
2)
14
6
(4
8)
>
20
m
et
as
ta
se
s
37
(2
6)
12
(1
9)
19
8
(3
2)
92
(3
0)
Su
pe
rs
ca
n
10
(7
)
3
(5
)
54
(9
)
30
(1
0)
W
H
O
la
d
d
er
fo
r
ca
nc
er
pa
in
,n
(%
)
0
0
(0
)
0
(0
)
12
(2
)
2
(1
)
1
70
(4
9)
31
(4
8)
25
7
(4
2)
13
7
(4
5)
2
37
(2
6)
20
(3
1)
15
1
(2
5)
78
(2
5)
3
35
(2
5)
13
(2
0)
19
4
(3
2)
90
(2
9)
To
ta
l
A
L
P
2
20
U
/
L
,n
(%
)
41
(2
9)
17
(2
7)
34
8
(5
7)
16
9
(5
5)
C
ur
re
nt
bi
sp
ho
sp
ho
na
te
us
e,
n
(%
)
69
(4
9)
30
(4
7)
25
0
(4
1)
12
4
(4
0)
Pr
io
r
d
oc
et
ax
el
,n
(%
)
87
(6
1)
37
(5
8)
35
2
(5
7)
17
4
(5
7)
E
B
R
T
1
2
w
ee
ks
of
sc
re
en
in
g,
n
(%
)
19
(1
3)
5
(8
)
99
(1
6)
49
(1
6)
Pl
at
el
et
s,
m
ed
ia
n
(r
an
ge
)
10
9 /
L
b
24
4
(9
9–
56
0)
25
1
(1
08
–
45
9)
24
4
(6
9–
64
5)
24
0
(5
1–
58
0)
N
eu
tr
op
hi
ls
,m
ed
ia
n
(r
an
ge
)
10
9 /
L
b
4.
1
(1
.7
–
13
.7
)
4.
1
(2
.1
–
9.
7)
4.
5
(1
.2
–
17
.1
)
4.
6
(1
.4
–
14
.3
)
H
em
og
lo
bi
n,
m
ed
ia
n
(r
an
ge
),
g/
d
L
12
.6
(9
.0
–
15
.7
)
12
.6
(8
.7
–
15
.4
)
12
.2
(8
.5
–
15
.7
)
12
.1
(8
.5
–
16
.4
)
A
lb
um
in
,m
ed
ia
n
(r
an
ge
),
g/
L
40
(2
4–
53
)
40
.9
(2
8–
49
)
40
(2
4–
53
)
40
(2
3–
50
)
To
ta
l
A
L
P,
m
ed
ia
n
(r
an
ge
),
U
/
L
11
9.
0
(3
2.
0–
26
81
.0
)
13
9.
5
(3
6.
0–
21
65
.6
)
21
1.
0
(3
2–
64
31
)
22
3.
0
(2
9–
48
05
)
L
D
H
,m
ed
ia
n
(r
an
ge
),
U
/
L
28
4.
0
(1
35
.0
–
12
97
.0
)
32
2.
5
(1
32
.0
–
10
22
.0
)
31
5.
5
(1
08
–
21
71
)
33
5.
5
(1
32
–
38
56
)
PS
A
,m
ed
ia
n
(r
an
ge
),
m
g/
L
85
.6
(4
.1
–
84
8.
0)
66
.4
(3
.6
–
34
57
.0
)
14
6.
3
(3
.8
–
60
26
.0
)
17
2.
9
(1
.5
–
14
50
0.
0)
A
L
P,
al
ka
lin
e
ph
os
ph
at
as
e;
E
B
R
T,
ex
te
rn
al
be
am
ra
d
ia
ti
on
th
er
ap
y;
E
C
O
G
PS
,E
as
te
rn
C
oo
pe
ra
ti
ve
O
nc
ol
og
y
G
ro
up
pe
rf
or
m
an
ce
st
at
us
;L
D
H
,l
ac
ta
te
d
eh
yd
ro
ge
na
se
;P
SA
,
pr
os
ta
te
-s
pe
ci
fi
c
an
ti
ge
n;
W
H
O
,W
or
ld
H
ea
lt
h
O
rg
an
iz
at
io
n.
a B
as
el
in
e
is
d
ef
in
ed
as
th
e
ti
m
e
th
e
pa
ti
en
ts
en
te
re
d
th
e
st
ud
y.
b
Se
le
ct
ed
d
at
a
fr
om
th
e
A
L
SY
M
PC
A
sa
fe
ty
po
pu
la
ti
on
.
Chemotherapy After Radium-223 in mCRPC 909
The Prostate
up to 18 months following first post-study drug
chemotherapy was generally low (< 10%), but tended
to be more common among patients in the radium-
223 group (Table V). Grades 3 or 4 hemoglobin,
neutrophil, and platelet values were recorded in 8%,
10%, and 6% of radium-223 and 4%, 2%, and 2% of
placebo patients, respectively (Table V). No statisti-
cally significant differences were found between
treatment groups in frequency of hematologic labora-
tory values corresponding to grade 3 or 4 AEs
(Table V). Maximum percentage decreases from base-
line in platelets were numerically greater in the
radium-223 group than in the placebo group, but did
not appear to be associated with prior docetaxel
treatment (prior docetaxel: yes, P¼ 0.400; no,
P¼ 0.350) (Fig. 2C and D). Hemoglobin and neutro-
phils were similar in the two treatment groups,
indicating little effect of radium-223 treatment on
hematologic toxicity of subsequent chemotherapy
(Fig. 2A and B).
Hematologic laboratory values were also assessed
according to docetaxel use prior to enrollment in
ALSYMPCA. Among the patients in the chemother-
apy post-study drug subgroup, 87/142 (61%) in the
radium-223 group and 37/64 (58%) in the placebo
group received docetaxel prior to receiving the study
drug. Hematologic parameters for patients who re-
ceived docetaxel prior to radium-223 were similar to
those for patients who did not, with no apparent
differences between treatment groups up to 18 months
(Supplementary Table SII).
Survival
Incidence and cause of death were similar between
treatment groups, during and within 30 days of
TABLE II. Extent of Study Drug Exposure for Patients in the Chemotherapy Post-Study Drug Subgroup Versus the
ALSYMPCA Intent-to-Treat (ITT) Population
Chemotherapy post-study
drug subgroup ALSYMPCA ITT population
Radium-223
n¼ 142
Placebo
n¼ 64
Radium-223
N¼ 614
Placebo
N¼ 307
Number of study injections, median (range) 6 (2–6) 6 (1–6) 6 (0–6) 5 (0–6)
Duration of study treatment, median (range), days 141 (28–177) 141 (1–175) 141 (1–196) 129 (1–190)
Number of study drug injections received, n (%)
1 0 (0) 3 (5) 18 (3) 21 (7)
2 6 (4) 8 (12) 37 (6) 36 (12)
3 9 (6) 7 (11) 48 (8) 37 (12)
4 9 (6) 3 (5) 60 (10) 34 (11)
5 6 (4) 6 (9) 47 (8) 29 (9)
6 112 (79) 37 (58) 389 (63) 145 (47)
TABLE III. Timing and Duration of Post-Study Drug Chemotherapya
Radium-223
n¼ 142
Placebo
n¼ 64
All chemotherapies, n 142 64
Time from randomization to start of chemotherapy, median (range), months 9.1 (1.8–35.6) 7.5 (1.6–26.4)
Time from end of study treatment to start of chemotherapy, median (range), months 3.8 (0–30.4) 2.6 (0.1–20.5)
Duration of first chemotherapy, median (range), months 4.6 (0–59.0) 4.2 (0–60.8)
Time from first chemotherapy to stop of last chemotherapy, median (range), months 6.2 (0–60.9) 8.5 (0–60.8)
Docetaxel, n 100 46
Time from randomization to start of docetaxel, median (range), months 9.2 (1.9–35.6) 7.3 (1.6–24.7)
Time from end of study treatment to start of docetaxel treatment, median (range), months 3.9 (0–30.4) 2.4 (0.1–19.3)
Duration of first docetaxel treatment, median (range), months 5.0 (0–59.0) 4.5 (0–60.8)
Time from first docetaxel treatment to stop of last docetaxel treatment, median (range),
months
5.8 (0–60.9) 4.9 (0–60.8)
aFor some patients with missing treatment end date, duration was calculated from start of treatment (any chemotherapy or docetaxel)
until data cutoff date, contributing to long range values.
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completing chemotherapy (Table VI). In the
radium-223 group, 29% of patients died while receiv-
ing chemotherapy, as did a similar proportion of
patients in the placebo group (33%). The most com-
mon cause of death was prostate cancer-related death
in 90% and 95% of patients in the radium-223 and
placebo groups, respectively. The proportion of
patients who died of nonskeletal metastases was
higher in the placebo group (24%) than in the radium-
223 group (15%).
Prior treatment with radium-223 did not appear
to have a detrimental effect on overall survival
with subsequent chemotherapy, when compared with
chemotherapy following placebo. Median overall
survival from start of chemotherapy was 16.0 months
in patients previously treated with radium-223
and 15.8 months in patients previously treated with
placebo.
Docetaxel Following Study Treatment
The most common chemotherapy agent adminis-
tered following study treatment in ALSYMPCA was
docetaxel; therefore, the safety of docetaxel following
radium-223 treatment was specifically assessed.
Patients in this docetaxel post-study drug subgroup
may have also received subsequent chemotherapy
with other agents, so data presented here do not
TABLE IV. Median Hematologic Values for Patients in the Chemotherapy Post-Study Drug Subgroup
Radium-223 (n¼ 142) Placebo (n¼ 64)
Parameter N Median (range) N Median (range)
Hemoglobin, g/dL
Baselinea 142 11.2 (6.4–108.0) 64 11.4 (7.7–15.2)
Month 2 82 10.6 (6.6–14.2) 42 10.8 (7.7–14.2)
Month 4 69 11.0 (6.4–86.0) 25 10.4 (7.1–14.6)
Month 6 50 10.9 (8.5–121.0) 22 10.9 (8.4–14.0)
Month 8 35 10.8 (7.1–12.9) 10 11.1 (9.6–13.1)
Month 10 30 10.8 (7.0–13.6) 17 11.7 (9.2–13.3)
Month 12 28 10.9 (7.8–13.2) 8 10.1 (8.0–13.4)
Month 14 25 11.1 (6.8–13.4) 6 12.0 (11.0–14.0)
Month 16 12 10.8 (8.6–94.0) 3 11.1 (9.3–12.2)
Month 18 17 11.2 (8.9–117.0) 8 10.9 (9.3–13.5)
Neutrophils (absolute) 109/L
Baselinea 142 3.6 (0.9–26.0) 64 4.5 (1.9–12.5)
Month 2 78 4.4 (0.5–24.4) 38 5.8 (0.5–13.1)
Month 4 66 3.9 (0.1–12.7) 23 5.2 (1.1–12.5)
Month 6 46 4.1 (0.5–16.1) 19 4.8 (1.5–12.2)
Month 8 33 4.1 (1.9–10.7) 9 3.9 (3.0–8.3)
Month 10 27 3.7 (0.2–8.9) 16 4.0 (3.0–8.5)
Month 12 24 4.6 (2.0–8.0) 8 3.6 (2.8–8.9)
Month 14 19 3.6 (0.9–7.4) 5 4.2 (3.1–7.0)
Month 16 11 4.2 (2.9–7.7) 3 4.3 (2.6–7.0)
Month 18 14 3.6 (1.1–8.3) 7 3.8 (2.4–9.2)
Platelets 109/L
Baselinea 142 215.0 (0.2–782.0) 64 235.5 (48.0–432.0)
Month 2 82 198.5 (0.3–692.0) 42 250.0 (48.0–385.0)
Month 4 69 209.0 (48.0–458.0) 25 220.0 (131.0–411.0)
Month 6 50 215.5 (55.0–494.0) 22 227.0 (99.0–334.0)
Month 8 35 209.0 (0.3–512.0) 10 225.5 (92.0–565.0)
Month 10 29 223.0 (0.2–668.0) 17 239.0 (130.0–512.0)
Month 12 28 215.0 (50.0–464.0) 8 214.5 (89.0–373.0)
Month 14 25 217.0 (26.0–452.0) 6 214.5 (159.0–341.0)
Month 16 12 230.5 (98.0–419.0) 3 314.0 (139.0–326.0)
Month 18 17 246.0 (78.0–601.0) 8 311.0 (143.0–378.0)
aLast nonmissing measurement prior to start of first post-study drug chemotherapy. Months 2–18 represent 2-month time windows
following first date of chemotherapy. Timing of hematology laboratory values is determined according to start of chemotherapy, not
by protocol-defined visits.
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reflect a pure population of patients treated with
docetaxel alone.
Demographics and baseline characteristics, study
drug exposure, and disposition were similar to those
in the chemotherapy post-study drug subgroup (Sup-
plementary Tables SIII–SV). Consistent with the che-
motherapy post-study drug subgroup, there was a
longer time from randomization to start of docetaxel
for patients in the radium-223 group (9.2 months)
compared with the placebo group (7.3 months). The
median time from the last dose of study drug to the
first dose of docetaxel was 3.9 months for the radium-
TABLE V. Percentage of Patients With Hematologic Laboratory Values Corresponding to Grades 3 and 4 Adverse
Events in the Chemotherapy Post-Study Drug Subgroup
Radium-223 (n¼ 142) Placebo (n¼ 64)
Parameter N n (%) N n (%)
Hemoglobin, <8–6.5 g/dL or <6.5 g/dL
Baselinea 142 4 (3) 64 1 (2)
Month 2 82 5 (6) 42 1 (2)
Month 4 69 3 (4) 25 1 (4)
Month 6 50 0 (0) 22 0 (0)
Month 8 35 1 (3) 10 0 (0)
Month 10 30 2 (7) 17 0 (0)
Month 12 28 1 (4) 8 0 (0)
Month 14 25 2 (8) 6 0 (0)
Month 16 12 0 (0) 3 0 (0)
Month 18 17 0 (0) 8 0 (0)
Total individual patientsb 116 9 (8) 49 2 (4)
P valuec 0.509
Neutrophils (absolute)< 1–0.5  109/L or< 0.5  109/L
Baselinea 142 1 (1) 64 0 (0)
Month 2 78 5 (6) 38 1 (3)
Month 4 66 2 (3) 23 0 (0)
Month 6 46 1 (2) 19 0 (0)
Month 8 33 0 (0) 9 0 (0)
Month 10 27 2 (7) 16 0 (0)
Month 12 24 0 (0) 8 0 (0)
Month 14 19 1 (5) 5 0 (0)
Month 16 11 0 (0) 3 0 (0)
Month 18 14 0 (0) 7 0 (0)
Total individual patientsb 114 11 (10) 48 1 (2)
P valuec 0.112
Platelets< 50–25  109/L or < 25  109/L
Baselinea 142 1 (1) 64 1 (2)
Month 2 82 4 (5) 42 1 (2)
Month 4 69 1 (1) 25 0 (0)
Month 6 50 0 (0) 22 0 (0)
Month 8 35 2 (6) 10 0 (0)
Month 10 29 1 (3) 17 0 (0)
Month 12 28 0 (0) 8 0 (0)
Month 14 25 1 (4) 6 0 (0)
Month 16 12 0 (0) 3 0 (0)
Month 18 17 0 (0) 8 0 (0)
Total individual patientsb 116 7 (6) 49 1 (2)
P valuec 0.438
aLast nonmissing measurement prior to start of first post-study drug chemotherapy. Months 2–18 represent 2-month time windows
following first date of chemotherapy. Timing of hematology laboratory values is determined according to start of chemotherapy, not
by protocol-defined visits.
bTotal individual patients with any post-baseline laboratory measurement.
cP values reflect data in the row above (total individual patients with post-baseline laboratory measurement).
912 Sartor et al.
The Prostate
Fig. 2. Maximum percentage decrease from baseline values for hemoglobin (A), neutrophils (B), platelets (C), and platelets by prior
docetaxel treatment (D).
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223 group and 2.4 months for the placebo group. The
median duration of first docetaxel therapy was 5.0
months in the radium-223 group and 4.5 months in
the placebo group (Table III).
Hematologic assessments for patients with doce-
taxel following study treatment were consistent with
the overall chemotherapy post-study drug subgroup.
Median hematologic values remained generally con-
stant over time, regardless of prior docetaxel exposure
(Supplementary Tables SVI and SVII). Maximum
percentage decreases from baseline in hemoglobin
and neutrophils were similar between radium-223
and placebo patients (Supplementary Fig. S1A and B).
The maximum percentage decrease in platelet counts
was somewhat greater in radium-223 patients, consis-
tent with the entire chemotherapy post-study drug
subgroup, and did not appear to be associated with
prior docetaxel treatment (prior docetaxel: yes,
P¼ 0.279; no P¼ 0.197) (Supplementary Fig. SIC and
D). The decrease in platelets in this subgroup and in
the overall chemotherapy post-study drug subgroup
was likely a consequence of radium-223 treatment,
rather than of docetaxel following radium-223, as a
higher incidence of grades 3–4 thrombocytopenia
(although in <10% of patients) was reported with
radium-223 versus placebo in ALSYMPCA [4].
For the docetaxel post-study drug subgroup, me-
dian overall survival from start of docetaxel was 17.5
and 16.7 months in patients previously treated with
radium-223 or placebo, respectively. Prostate cancer-
related death remained the most common cause of
death in both treatment groups (Supplementary
Table SVIII).
DISCUSSION
In this exploratory analysis, no safety concerns
were identified with chemotherapy following ra-
dium-223, and no detrimental effects on overall
survival were observed. These findings represent an
initial step in defining how radium-223 affects the
safety of subsequent chemotherapy, an issue that will
be further addressed as radium-223 is used earlier in
the treatment of patients with CRPC [16].
Of note, among the 142 radium-223 patients who
received subsequent chemotherapy, most (79%) had
received all six planned radium-223 doses, which is
the recommended regimen in the product label and as
used in the ALSYMPCA trial. Interestingly, a substan-
tial proportion (61%) of patients received docetaxel
before radium-223 and received subsequent chemo-
therapy following radium-223 treatment; 39% of
patients who received chemotherapy following ra-
dium-223 were chemotherapy na€ıve. Data presented
here indicate that the use of chemotherapy following
radium-223 is feasible regardless of prior docetaxel
use.
Several limitations of this exploratory analysis need
to be considered in interpreting its findings regarding
broader questions of treatment sequencing. The che-
motherapy post-study drug subgroup of ALSYMPCA
may have been affected by post-randomization fac-
tors; therefore, the comparability of radium-223 and
placebo patients who received subsequent chemother-
apy is not assured by the initial randomization of the
original study. Hematologic data used in the explor-
atory analysis were recorded at intervals specified by
the ALSYMPCA follow-up schedule, rather than as
time points determined for the optimal assessment of
the hematologic toxicity related to chemotherapy.
Consequently, sample collections may not have coin-
cided with the expected nadirs in hemoglobin, neutro-
phil, and platelet counts. In addition, the median
values reported may obscure a small number of
patients who may have had severe but transient
myelosuppression following chemotherapy. Data for
TABLE VI. Deaths During or Within 30 Days of Completing Chemotherapy in the Chemotherapy Post-Study Drug
Subgroup
Radium-223
n¼ 142
Placebo
n¼ 64
Number (%) of deaths while still on chemotherapy 41 (29) 21 (33)
Prostate cancer-related death, n (%) 37 (90) 20 (95)
Skeletal metastases 31 (76) 15 (71)
Other metastases 6 (15) 5 (24)
Non-prostate cancer-related death, n (%) 4 (10) 1 (5)
Bronchopneumonia 1 (2) 0 (0)
Cardiopulmonary failure 0 (0) 1 (5)
Cerebral hemorrhage 1 (2) 0 (0)
Respiratory failure 1 (2) 0 (0)
Sepsis 1 (2) 0 (0)
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precise dosing and intervals of the chemotherapy
regimens were not collected. Because of a high patient
dropout rate during the follow-up period, the analysis
was not designed with the statistical power to fully
assess hematologic safety between radium-223 and
placebo in the chemotherapy post-study drug sub-
group. The safe use of other agents following treat-
ment with radium-223 remains to be studied. Agents
with potential myelosuppressive effects include cab-
azitaxel, and poly(ADP-ribose) polymerase inhibitors
such as olaparib.
Radium-223 significantly prolonged median over-
all survival compared with placebo, irrespective of
prior treatment with docetaxel (prior docetaxel: HR
0.70; 95%CI: 0.56–0.88; P¼ 0.002; no prior docetaxel:
HR 0.69; 95%CI: 0.52–0.92; P¼ 0.01) [11]. The
ALSYMPCA trial also showed that patients who
received prior docetaxel had more hematologic toxic-
ity than those who were docetaxel na€ıve, although the
incidence of grade three or four thrombocytopenia
was less than 10% in both groups [4,11]. The data in
the present safety analysis in the chemotherapy post-
study drug subgroup suggest that chemotherapy may
be safely given after radium-223, an important finding
especially if radium-223 is to be considered earlier in
the course of the disease. Additionally, survival with
chemotherapy was similar between treatment groups,
suggesting that prior treatment with radium-223 did
not compromise the efficacy of subsequent chemo-
therapy. At this time, although we know from
ALSYMPCA that radium-223 can be safely adminis-
tered before or after docetaxel, and that docetaxel
may be safely administered before radium-223 [11],
we support the concept of prospective studies to fully
understand the efficacy and safety of chemotherapy
following radium-223 treatment.
CONCLUSION
This exploratory analysis of ALSYMPCA data
represents the first and only evaluation of the safety
of chemotherapy following radium-223 treatment,
and identifies no significant safety concerns; thus, the
use of chemotherapy after radium-223 is not contra-
indicated.
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